Almac Diagnostic Services Launches Sample Management Service

July 31, 2019

Almac Diagnostic Services Launches Sample Management Service to Streamline Biomarker Programmes for Clients

Craigavon, N.I., 31 July 2019 – Almac Diagnostic Services, a global stratified medicine company and member of the Almac Group, today announced the launch of its Sample Management Service. 

This latest support offering includes pathology review & digital pathology, sample receipt and accessioning, sample storage and downstream processing. The service provides clients with the reassurance that samples are being stored safely, with reliable up-to-date information about sample inventory, ultimately enabling ready access to samples upon request.

Almac Diagnostic Services has over 15 years’ experience in sample preparation, analysis and reporting and as part of the Sample Management Service, offers a dedicated point of contact throughout an entire project.  This, coupled with Almac’s unique LIMS barcode system, ensures sample traceability and full chain of custody, alongside bespoke data management reporting to suit client’s exact requirements.

A range of secure storage solutions are available at Almac Diagnostic Services’ facilities to suit individual study needs including ambient and cold storage which are temperature controlled, fully validated and HTA compliant, and monitored 24/7.

Whether clients are benefitting from Almac Diagnostic Services’ downstream sample processing services such as DNA/RNA extraction, DNA panel /RNA panel Next Generation Sequencing, Whole Exome Sequencing (WES) or if they require the analysis to be performed externally with another vendor, the new Sample Management Service helps coordinate these activities on the client’s behalf.

Dr Leeona Galligan, VP UK Operations, Almac Diagnostic Services, commented “The addition of this Sample Management Service to our growing portfolio of service offerings is further evidence of our commitment to provide a fully integrated laboratory service to our global biopharma client base.  We have established a dedicated team to deliver this offering which will ultimately help simplify and streamline the clinical trial process for our customers and I am delighted to launch this new service.”

To find out more about Almac Diagnostic Services’ Sample Management Service, please visit:



About Almac Diagnostic Services

Almac Diagnostic Services is a global stratified medicine company specialising in biomarker driven clinical trials. The company is focused on the discovery, development and commercialisation of diagnostic and companion diagnostic tests.

We partner with biopharma companies to provide solutions ranging from biomarker discovery to CDx development including regulatory submissions and commercialisation. We also facilitate biomarker clinical trial management and clinical test delivery from our CLIA-accredited labs.

The tests developed at Almac Diagnostic Services have a wide range of applications including patient selection, and are utilised in phase I to phase III registrational clinical trials.

For more information visit:

About Almac Group

A unique culture delivering exceptional solutions

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Our innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation that has grown organically over the past five decades now employing over 5600 highly skilled personnel across 18 facilities including Europe, the US and Asia.

We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.

To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit


Back to news